Q1 2026 · 13F-HR
Samsara BioCapital, LLCholdings as filed
Filed 2026-05-15 · accession 0001744967-26-000005
$1.03B
Reported value
22
Positions
2026-03-31
Period end
The Brief · Samsara BioCapital, LLC · Q1 2026
AI · grounded in 13F
Samsara BioCapital, LLC established a new position in SGP valued at $54.67M. The fund also opened new stakes in AGMB for $6.29M and CHRS for $5.79M. On the selling side, the fund trimmed its holding in PVLA by 63.33% and closed its position in CTNM, reducing exposure by $825,760.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 80706P103 | SRRK | SCHOLAR ROCK HLDG CORP | $339.1M | 32.9% | 6,897,652 | Common | SOLE |
| 603170101 | MLYS | MINERALYS THERAPEUTICS INC | $159.0M | 15.5% | 5,871,018 | Common | SOLE |
| 022307102 | ALMS | ALUMIS INC | $139.8M | 13.6% | 6,345,219 | Common | SOLE |
| 81734D104 | SEPN | SEPTERNA INC | $75.7M | 7.35% | 3,149,128 | Common | SOLE |
| 482929106 | KLRS | KALARIS THERAPEUTICS INC | $74.7M | 7.26% | 12,948,081 | Common | SOLE |
| 85220G109 | SGP | SPYGLASS PHARMA INC | $54.7M | 5.31% | 2,109,953 | Common | SOLE |
| 64135M105 | NGNE | NEUROGENE INC | $34.6M | 3.36% | 1,717,127 | Common | SOLE |
| 46124U107 | IVA | INVENTIVA SA | $28.8M | 2.80% | 5,194,805 | Common | SOLE |
| 869367201 | STRO | SUTRO BIOPHARMA INC | $26.5M | 2.57% | 1,062,872 | Common | SOLE |
| 008064206 | JBIO | JADE BIOSCIENCES INC | $13.6M | 1.32% | 968,798 | Common | SOLE |
| 918385204 | VTVT | VTV THERAPEUTICS INC | $11.8M | 1.15% | 298,496 | Common | SOLE |
| 03843E104 | AQST | AQUESTIVE THERAPEUTICS INC | $10.4M | 1.01% | 2,500,000 | Common | SOLE |
| 98420X202 | XFOR | X4 PHARMACEUTICALS INC | $7.6M | 0.74% | 1,832,566 | Common | SOLE |
| 65487U108 | NKTX | NKARTA INC | $7.4M | 0.72% | 3,507,666 | Common | SOLE |
| 03940C100 | ACLXGBX | ARCELLX INC | $7.0M | 0.68% | 60,873 | Common | SOLE |
| 91678A107 | UPB | UPSTREAM BIO INC | $6.6M | 0.64% | 736,047 | Common | SOLE |
| 00370M103 | ABVX | ABIVAX SA | $6.3M | 0.61% | 56,581 | Common | SOLE |
| 00860C102 | AGMB | AGOMAB THERAPEUTICS NV | $6.3M | 0.61% | 600,000 | Common | SOLE |
| 753018100 | RANI | RANI THERAPEUTICS HLDGS INC | $6.2M | 0.61% | 8,500,000 | Common | SOLE |
| 19249H103 | CHRS | COHERUS ONCOLOGY INC | $5.8M | 0.56% | 3,428,571 | Common | SOLE |
| 697947109 | PVLA | PALVELLA THERAPEUTICS INC NE | $4.8M | 0.47% | 38,432 | Common | SOLE |
| 38341P102 | GOSS | GOSSAMER BIO INC | $2.4M | 0.23% | 7,222,559 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.